Ms Jennifer Chu > Debevoise & Plimpton LLP > New York, United States > Lawyer Profile

Debevoise & Plimpton LLP clients have ‘immense trust’ in the private equity group’s capacity to handle the most diverse range of complex transactions, spanning public and private buyouts, PIPEs, multi-asset acquisitions, continuation funds, and other bespoke investments. In addition to a broad scope of expertise, the firm is able to offer clients a wealth of industry-specific experience to navigate convoluted regulatory landscapes, including such areas as healthcare, insurance, technology, and renewables. The highly respected Kevin Schmidt leads the team, who is adept at handling high-value M&A and fosters strong working relationships with market giants such as Blackstone, Brookfield and Carlyle. Healthcare and life sciences specialist Kevin Rinker , as well as Uri Herzberg who is vastly experienced across the gamut of transactional matters, led with Schmidt in CD&R’s $3.7bn acquisition of a majority stake in Roper Technologies. Paul Bird has a particularly diverse practice, renowned for his cross-border capabilities and significant corporate matters such as leveraged buyouts, spin-offs and takeover defense. Jennifer Chu continues to establish her reputation in the market for advising PE firms on M&A and joint ventures, while Christopher Anthony practice focuses on acquisitions, divestitures and joint ventures. All lawyers are based in New York.

The chiefly New York-based team at Debevoise & Plimpton LLP assist clients with the full spectrum of corporate healthcare and life sciences matters, including regulatory compliance on transactions and divestitures, and cases involving fraud and unjust enrichment claims. Mark Goodman handles commercial disputes and government investigations alongside Maura Monaghan. Kevin Rinker handles a number of life sciences M&A deals and private equity buyouts, while Andrew Bab focuses on corporate and private equity related matters, bolstered by Jennifer Chu. Washington DC’s Paul Rubin, who heads the FDA regulatory side of the practice, often advises private equity funds on transactions involving life sciences entities.